INFLAMMOPHARMACOLOGY

Scope & Guideline

Exploring breakthroughs in inflammation research and therapeutics.

Introduction

Explore the comprehensive scope of INFLAMMOPHARMACOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore INFLAMMOPHARMACOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0925-4692
PublisherSPRINGER BASEL AG
Support Open AccessNo
CountrySwitzerland
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINFLAMMOPHARMACOLOGY / Inflammopharmacology
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPICASSOPLATZ 4, BASEL 4052, SWITZERLAND

Aims and Scopes

INFLAMMOPHARMACOLOGY focuses on the pharmacological aspects of inflammation and its modulation through various therapeutic agents, particularly emphasizing the mechanisms underlying anti-inflammatory actions. The journal encompasses a wide range of studies exploring both traditional and novel treatment strategies for inflammatory diseases, including but not limited to rheumatoid arthritis, neuroinflammation, and inflammatory bowel diseases.
  1. Pharmacological studies on anti-inflammatory agents:
    Research articles investigating the efficacy and safety of pharmacological agents, including traditional non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and emerging therapies like biologics and small molecules.
  2. Natural products and herbal medicine:
    Exploration of the anti-inflammatory properties of natural compounds and extracts from various plants, including traditional medicinal herbs, and their potential applications in treating inflammatory conditions.
  3. Mechanistic studies of inflammation:
    Detailed investigations into the cellular and molecular pathways involved in inflammation, including the role of cytokines, signaling pathways (such as NF-κB and NLRP3), and the immune response.
  4. Clinical trials and translational research:
    Reports on clinical trials assessing the effectiveness of new treatments for inflammatory diseases, including studies that bridge laboratory findings with clinical applications.
  5. Innovative therapeutic strategies:
    Research on novel therapies, including nanomedicine, gene therapy, and repurposing existing drugs for new indications in the context of inflammation.
The journal INFLAMMOPHARMACOLOGY is witnessing several emerging themes that reflect current scientific trends and societal needs, particularly in the context of the ongoing COVID-19 pandemic and advancements in therapeutic approaches.
  1. Research on COVID-19 and inflammatory responses:
    A significant increase in studies concerning the inflammatory responses associated with COVID-19, including the role of cytokine storms and the therapeutic potential of anti-inflammatory agents in managing COVID-19 complications.
  2. Focus on neuroinflammation and neurodegenerative diseases:
    Growing interest in the relationship between inflammation and neurodegenerative diseases like Alzheimer's and Parkinson's, with an emphasis on understanding the underlying mechanisms and exploring potential neuroprotective therapies.
  3. Exploration of gut-brain axis and inflammation:
    Emerging research on the gut-brain axis and its implications for inflammatory diseases, particularly in understanding how gut microbiota can influence systemic inflammation and neurological health.
  4. Novel therapeutic modalities and drug repurposing:
    Increased focus on innovative therapeutic strategies, including drug repurposing for inflammatory diseases, utilizing existing medications in new contexts to enhance treatment efficacy.
  5. Natural products and phytotherapy:
    A resurgence in interest towards natural products and phytochemicals for their anti-inflammatory properties, reflecting a growing trend towards integrative and holistic approaches to health.

Declining or Waning

While INFLAMMOPHARMACOLOGY continues to thrive in many areas, certain themes are showing signs of reduced emphasis in recent publications. These waning scopes suggest a shift in focus within the journal's research community.
  1. Conventional DMARDs studies:
    Research on conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) appears to be declining, possibly due to the increasing interest in biologics and targeted therapies that offer more personalized and effective treatment options for autoimmune conditions.
  2. Basic research on inflammation without therapeutic implications:
    There seems to be a waning interest in purely basic research studies that do not directly translate to therapeutic applications or clinical implications, as the journal shifts towards more clinically relevant findings.
  3. Vaccine-related inflammation studies:
    As vaccine development and research have become more established, the focus on inflammation specifically related to vaccine responses has decreased, possibly as the field matures and becomes less of a novelty.
  4. Historical perspectives and reviews:
    While historical reviews have their place, the trend indicates a decreasing number of purely historical or retrospective studies, as the journal emphasizes current research trends and forward-looking therapeutic strategies.

Similar Journals

Fitoterapia

Cultivating Insights into Medicinal Plants
Publisher: ELSEVIERISSN: 0367-326XFrequency: 8 issues/year

Fitoterapia is a prestigious journal published by Elsevier that specializes in the fields of drug discovery and pharmacology. Established in 1948 and featuring a comprehensive scope that encompasses all aspects of medicinal plants and their derivatives, this journal is a critical resource for researchers, professionals, and students interested in the pharmacological effects of natural products. With an impressive impact factor reflected in its Q2 ranking in both Drug Discovery and Medicine as well as a Q3 ranking in Pharmacology, Fitoterapia plays a vital role in promoting innovative research in the intersection of traditional medicine and modern pharmacological science. The journal’s commitment to quality is further highlighted by its rankings in Scopus, where it holds a notable position among peers in its field. Although Fitoterapia does not currently offer Open Access, its reputation for rigor and relevance makes it an indispensable asset for anyone engaged in herbal medicine research and development. Authors and researchers seeking to publish groundbreaking findings will find a welcoming platform to disseminate their work in this influential journal.

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Pioneering Research at the Intersection of Immunology and Toxicology
Publisher: TAYLOR & FRANCIS LTDISSN: 0892-3973Frequency: 4 issues/year

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

PHARMACEUTICAL BIOLOGY

Bridging the Gap Between Biology and Pharmaceutical Applications
Publisher: TAYLOR & FRANCIS LTDISSN: 1388-0209Frequency: 1 issue/year

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.

MOLECULAR THERAPY

Empowering breakthroughs in genetics and pharmacology.
Publisher: CELL PRESSISSN: 1525-0016Frequency: 12 issues/year

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Elevating Research through Expert Analysis
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Iranian Journal of Pharmaceutical Research

Connecting scholars to elevate the standards of drug research.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Fostering Collaboration in Drug Development
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

INFLAMMATION RESEARCH

Advancing knowledge in the realm of inflammation.
Publisher: SPRINGER BASEL AGISSN: 1023-3830Frequency: 12 issues/year

INFLAMMATION RESEARCH, published by SPRINGER BASEL AG, serves as a pivotal journal in the fields of Immunology and Pharmacology, with notable rankings of Q2 in Immunology and Q1 in Pharmacology as of 2023. With an ISSN of 1023-3830 and an E-ISSN of 1420-908X, this esteemed journal, located in Basel, Switzerland, has been at the forefront of advancing our understanding of inflammatory processes since its inception in 1995. Covering research trends and breakthroughs until 2024, it significantly contributes to both the theoretical frameworks and practical applications within its discipline, boasting a strong Scopus ranking of #40/313 in Pharmacology and #56/236 in Immunology, placing it in the top percentiles for its field. Although it does not offer Open Access options, the journal remains an invaluable resource for researchers, professionals, and students committed to unraveling the complexities of inflammation and its implications in health and disease.

Journal of Inflammation Research

Uncovering the Mechanisms of Inflammation for Better Health
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

ARCHIVES OF PHARMACAL RESEARCH

Exploring the frontiers of pharmacal science for a healthier future.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.